Most cited papers in Forensic Toxicology and Drug Analysis
What are the most cited papers in Forensic Toxicology and Drug Analysis?
The most cited paper in Forensic Toxicology and Drug Analysis is "Recent advances in the phencyclidine model of schizophrenia" (Daniel C. Javitt, Stephen R. Zukin, 1991), with 2,933 citations. Next come "Drugs of abuse: anatomy, pharmacology and function of reward pathways" (2,095) and "The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility" (2,027).
Showing 50 of 100 papers. Every paper with more than 604 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Recent advances in the phencyclidine model of schizophrenia Daniel C. Javitt, Stephen R. Zukin · American Journal of Psychiatry | Oct 1991 | 2,933 |
| 2 | Drugs of abuse: anatomy, pharmacology and function of reward pathways George F. Koob · Trends in Pharmacological Sciences | 1992 | 2,095 |
| 3 | The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility WHO ASSIST Working Group · Addiction | 30 Aug 2002 | 2,027 |
| 4 | Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Roland R. Griffiths, William A. Richards, U. McCann et al. · Psychopharmacology | 7 Jul 2006 | 1,716 |
| 5 | The reinstatement model of drug relapse: history, methodology and major findings Yavin Shaham, Uri Shalev, Lin Lü et al. · Psychopharmacology | 26 Oct 2002 | 1,644 |
| 6 | Formation and inactivation of endogenous cannabinoid anandamide in central neurons Vincenzo Di Marzo, Angelo Fontana, Hugues Cadas et al. · Nature | Dec 1994 | 1,589 |
| 7 | Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study Robin Lester Carhart-Harris, Mark Bolstridge, James Rucker et al. · The Lancet Psychiatry | 17 May 2016 | 1,581 |
| 8 | Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Luc F. Van Gaal, Aila Rissanen, André Jacques Scheen et al. · The Lancet | Apr 2005 | 1,504 |
| 9 | Trial of Psilocybin versus Escitalopram for Depression Robin Lester Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al. · New England Journal of Medicine | 14 Apr 2021 | 1,425 |
| 10 | Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction Avshalom Caspi, Terrie E. Moffitt, Mary D Cannon et al. · Biological Psychiatry | 19 Mar 2005 | 1,416 |
| 11 | Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies Louk J. M. J. Vanderschuren, Peter W. Kalivas · Psychopharmacology | 4 Aug 2000 | 1,350 |
| 12 | Development of a rational scale to assess the harm of drugs of potential misuse David Nutt, Leslie A. King, William Saulsbury et al. · The Lancet | Mar 2007 | 1,316 |
| 13 | Modulation of anxiety through blockade of anandamide hydrolysis Satish Kathuria, Silvana Gaetani, Darren Fegley et al. · Nature Medicine | 2 Dec 2002 | 1,296 |
| 14 | The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) A. Richard Green, Annis O. Mechan, J. Martin Elliott et al. · Pharmacological Reviews | 14 Aug 2003 | 1,280 |
| 15 | Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients Xavier Pi-Sunyer, Louis J. Aronne, Hassan Massoud Heshmati et al. · JAMA | 14 Feb 2006 | 1,225 |
| 16 | A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol Jacqueline L. Blankman, Gabriel M. Simon, Benjamin F. Cravatt · Chemistry & Biology | Dec 2007 | 1,182 |
| 17 | Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Michael P. Bogenschutz, Alyssa A. Forcehimes, Jessica A. Pommy et al. · Journal of Psychopharmacology | 13 Jan 2015 | 1,181 |
| 18 | Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression Guy M. Goodwin et al. · New England Journal of Medicine | 2 Nov 2022 | 1,168 |
| 19 | 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System William A. Watson, Toby L. Litovitz, George C. Rodgers et al. · The American Journal of Emergency Medicine | Sep 2005 | 1,149 |
| 20 | Human Cannabinoid Pharmacokinetics Marilyn Ann Huestis · Chemistry & Biodiversity | Aug 2007 | 1,101 |
| 21 | Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013 Deborah S. Hasin, Tulshi D. Saha, Bradley Townsend Kerridge et al. · JAMA Psychiatry | 21 Oct 2015 | 1,092 |
| 22 | State of the art in hair analysis for detection of drug and alcohol abuse Fritz Pragst, Marie Balı́ková · Clinica Chimica Acta | 8 Mar 2006 | 1,068 |
| 23 | Control of pain initiation by endogenous cannabinoids Antonio Calignano, Giovanna La Rana, Andrea Giuffrida et al. · Nature | Jul 1998 | 1,062 |
| 24 | The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis Daniel Ciccarone · Current Opinion in Psychiatry | 10 May 2021 | 1,026 |
| 25 | Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States Mahmoud A. ElSohly, Zlatko Mehmedic, Susan D. Foster et al. · Biological Psychiatry | 19 Jan 2016 | 1,014 |
| 26 | Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics Martin Schulz, Stefanie Iwersen‐Bergmann, Hilke Andresen et al. · Critical Care | 26 Jul 2012 | 1,011 |
| 27 | Psilocybin with psychological support for treatment-resistant depression: six-month follow-up Robin Lester Carhart-Harris, Mark Bolstridge, Camilla Day et al. · Psychopharmacology | 8 Nov 2017 | 994 |
| 28 | Cannabinoids and the expanded endocannabinoid system in neurological disorders Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo · Nature Reviews Neurology | 12 Dec 2019 | 992 |
| 29 | Cocaine and Other Stimulants Frank H. Gawin, Everett H. Ellinwood · New England Journal of Medicine | 5 May 1988 | 976 |
| 30 | Evolution of dispersive liquid–liquid microextraction method Mohammad Bagher Rezaee, Yadollah Yamini, Mohammad Faraji · Journal of Chromatography A | 4 Dec 2009 | 970 |
| 31 | Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects Roland R. Griffiths, Matthew W. Johnson, William A. Richards et al. · Psychopharmacology | 14 Jun 2011 | 962 |
| 32 | Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Jonathan Z. Long, Weiwei Li, Lamont Booker et al. · Nature Chemical Biology | 23 Nov 2008 | 949 |
| 33 | Pharmacology and effects of cannabis: A brief review C. Heather Ashton · The British Journal of Psychiatry | Feb 2001 | 944 |
| 34 | Cue-Induced Cocaine Craving: Neuroanatomical Specificity for Drug Users and Drug Stimuli Hugh P Garavan, John Pankiewicz, Alan S. Bloom et al. · American Journal of Psychiatry | Nov 2000 | 941 |
| 35 | Amphetamines and related compounds Edward F. Domino · Electroencephalography and Clinical Neurophysiology | Jun 1971 | 929 |
| 36 | Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin — Final Report Jennifer E. Layden, Isaac Ghinai, Ian Wright Pray et al. · New England Journal of Medicine | 6 Sep 2019 | 922 |
| 37 | Low Level of Brain Dopamine D2 Receptors in Methamphetamine Abusers: Association With Metabolism in the Orbitofrontal Cortex Nora D. Volkow, Linda Chang, Gene-Jack Wang et al. · American Journal of Psychiatry | Dec 2001 | 917 |
| 38 | Epidemiology ofDSM-5Drug Use Disorder Bridget F. Grant, Tulshi D. Saha, W. June Ruan et al. · JAMA Psychiatry | 18 Nov 2015 | 905 |
| 39 | Non‐medical use of prescription stimulants among US college students: prevalence and correlates from a national survey Sean Esteban McCabe, John Rogers Knight, Christian J. Teter et al. · Addiction | 10 Dec 2004 | 888 |
| 40 | Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Fernanda Palhano-Fontes et al. · Psychological Medicine | 15 Jun 2018 | 849 |
| 41 | Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities Aron J. Hall · JAMA | 9 Dec 2008 | 826 |
| 42 | Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners Yasuo Okamoto, Jun Morishita, Kazuhito Tsuboi et al. · Journal of Biological Chemistry | Feb 2004 | 814 |
| 43 | Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Francisco Arteaga Moreno, Christopher B. Wiegand, E. Keolani Taitano et al. · The Journal of Clinical Psychiatry | 15 Nov 2006 | 807 |
| 44 | Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys Louisa J Degenhardt et al. · PLoS Medicine | 26 Jun 2008 | 806 |
| 45 | Cardiovascular Complications of Cocaine Use Richard A. Lange, L.David Hillis · New England Journal of Medicine | 2 Aug 2001 | 804 |
| 46 | Medical Complications of Cocaine Abuse Louis L. Cregler, Herbert Mark · New England Journal of Medicine | 4 Dec 1986 | 796 |
| 47 | A review of the clinical pharmacology of methamphetamine Christopher Cruickshank, Kyle R. Dyer · Addiction | 29 Apr 2009 | 780 |
| 48 | An endocannabinoid mechanism for stress-induced analgesia Andrea G. Hohmann, Richard L. Suplita, Nathan M. Bolton et al. · Nature | Jun 2005 | 779 |
| 49 | Structural Abnormalities in the Brains of Human Subjects Who Use Methamphetamine Paul M. Thompson, Kiralee M. Hayashi, Sara L. Simon et al. · Journal of Neuroscience | 30 Jun 2004 | 770 |
| 50 | 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB 1 receptor Lumír Hanuš, Saleh Abu‐Lafi, Ester Fride et al. · Proceedings of the National Academy of Sciences | 20 Mar 2001 | 763 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.